Indolent Lymphoma-Pipeline Insights, 2016

Description:

“Indolent Lymphoma-Pipeline Insights, 2016” provides in depth insight on the pipeline drugs and their development activities around the Indolent Lymphoma. The report covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. The Report covers the product clinical trials information and other development activities including technology, licensing, collaboration, acquisitions, funding, patent and USFDA & EMA designations details. The Report also provides detailed information on the discontinued and dormant drugs that have gone inactive over the years for Indolent Lymphoma. The report also assesses the Indolent Lymphoma therapeutics by Monotherapy, Combination products, Molecule type and Route of Administration.

Scope

- The report provides competitive pipeline landscape of Indolent Lymphoma
- The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
- Coverage of the Indolent Lymphoma pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
- The report review the key players involved in the therapeutics development for Indolent Lymphoma and also provides company profiling
- The report also gives the information on dormant and discontinued pipeline projects
- Pipeline products coverage based on various stages of development ranging from pre registration till discovery and undisclosed stages
- Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type

Reasons to buy

- Complete Pipeline intelligence and complete understanding over therapeutic development for Indolent Lymphoma
- Identify the relationship between the drugs and its use for target finding, drug repurposing, and precision medicine.
- Devise corrective measure for pipeline projects by understanding Indolent Lymphoma pipeline depth and focus of Indication therapeutics
- Developing strategic initiatives to support your drug development activities.
- Optimizing the portfolio and keep in touch with the rapid changing pharmaceutical market, and make the best decision for your business.
- Develop and design in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Provides strategically significant competitor information, analysis, and insight to formulate effective R&D development strategies
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
- Gaining a clear picture of the competitive landscape for evidence based decisions

Contents:

- Indolent Lymphoma Overview
- Indolent Lymphoma Pipeline Therapeutics
- Indolent Lymphoma Therapeutics under Development by Companies
- Indolent Lymphoma Filed and Phase III Products
- Comparative Analysis
- Indolent Lymphoma Phase II Products
- Comparative Analysis
- Indolent Lymphoma Phase I and IND Filed Products
- Comparative Analysis
- Indolent Lymphoma Discovery and Pre-Clinical Stage Products
- Comparative Analysis
Drug Candidate Profiles
- Indolent Lymphoma – Therapeutics Assessment
- Assessment by Monotherapy Products
- Assessment by Combination Products
- Assessment by Route of Administration
- Assessment by Molecule Type
- Indolent Lymphoma – Discontinued Products
- Indolent Lymphoma – Dormant Products
- Companies Involved in Therapeutics Development for Indolent Lymphoma
- Appendix
- Methodology
- Contact Us
- Disclaimer

List of Tables
- Number of Products under Development for Indolent Lymphoma, 2016
- Number of Products under Development by Companies
- Comparative Analysis by Filed and Phase III Products, 2016
- Comparative Analysis Phase II Products, 2016
- Comparative Analysis Phase I and IND Filed Products, 2016
- Comparative Analysis Discovery and Pre-Clinical Stage Products, 2016
- Drug Candidates Profiles
- Indolent Lymphoma Assessment by Monotherapy Products
- Indolent Lymphoma Assessment by Combination Products
- Indolent Lymphoma Assessment by Route of Administration
- Indolent Lymphoma Assessment by Stage and Route of Administration
- Indolent Lymphoma Assessment by Molecule Type
- Indolent Lymphoma Assessment by Stage and Molecule Type
- Indolent Lymphoma Therapeutics – Discontinued Products
- Indolent Lymphoma Therapeutics – Dormant Products
- Products under Development by Companies, 2016

List of Figures
- Number of Products under Development for Indolent Lymphoma, 2016
- Filed and Phase III Products, 2016
- Phase II Products, 2016
- Phase I and IND Filed Products, 2016
- Discovery and Pre-Clinical Stage Products, 2016
- Indolent Lymphoma Assessment by Monotherapy Products
- Indolent Lymphoma Assessment by Combination Products
- Indolent Lymphoma Assessment by Route of Administration
- Indolent Lymphoma Assessment by Stage and Route of Administration
- Indolent Lymphoma Assessment by Molecule Type
- Indolent Lymphoma Assessment by Stage and Molecule Type

Ordering:
- Order Online - http://www.researchandmarkets.com/reports/3533099/
- Order by Fax - using the form below
- Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

- Product Name: Indolent Lymphoma-Pipeline Insights, 2016
- Web Address: http://www.researchandmarkets.com/reports/3533099/
- Office Code: SCPLJF9L

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Format</th>
<th>Quantity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User</td>
<td>USD 1250</td>
</tr>
<tr>
<td>Electronic (PDF) - Site License</td>
<td>USD 2500</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide</td>
<td>USD 4000</td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

- Title: Mr ☐ Mrs ☐ Dr ☐ Miss ☐ Ms ☐ Prof ☐
- First Name: __________________________ Last Name: __________________________
- Email Address: * __________________________
- Job Title: __________________________
- Organisation: __________________________
- Address: __________________________
- City: __________________________
- Postal / Zip Code: __________________________
- Country: __________________________
- Phone Number: __________________________
- Fax Number: __________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:
Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:
Marketing Code: ______________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World